With its long-standing commitment to addressing the needs of people living with diabetes, Sanofi announced today a new development and commercialization alliance at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Florida, U.S.

Sensile Medical, Sanofi and Verily (formerly Google Life Sciences) are collaborating on development and commercialization of a connected insulin patch pump.

The 3 parties develop and commercialize a new generation of “all-in-one” pre-filled insulin patch pump, primarily to serve people living with type 2 diabetes.

The alliance will leverage Sanofi’s expertise in patient-centered diabetes solutions and insulins, Sensile Medical’s leadership in developing micro-pump technologies for medical use, and Verily’s experience in micro-electronic integration and digital healthcare technology.

“Our goal is to develop a new type of pump technology that is simple to use and appropriate for people with Type 2 diabetes, as well as by those with Type 1 diabetes who are the primary users of insulin pumps today,” said Derek Brandt, CEO of Sensile Medical.

[socialpug_tweet tweet=”Our goal is to develop a new type of pump technology that is simple to use and appropriate for people with Type 2 diabetes, as well as by those with Type 1 diabetes who are the primary users of insulin pumps today,” said Derek Brandt, CEO of Sensile Medical.” display_tweet=”Our goal is to develop a new type of pump technology that is simple to use and appropriate for people with Type 2 diabetes, as well as by those with Type 1 diabetes who are the primary users of insulin pumps today,” said Derek Brandt, CEO of Sensile Medical.” style=”3″]

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here